Celldex Therapeutics (United States)

InstitutionResearch output, impact & collaborations

Celldex Therapeutics (United States) is a research organisation in Hampton, US. OpenAlex records 449 works and 60,922 citations for it. 286 researchers list it as their most recent affiliation.

449

Works

60,922

Citations

286

Researchers

65.3

Avg h-index

IDs:ROR OpenAlex

How has Celldex Therapeutics (United States)'s publication output changed over time?

ScholarIQpublication output · 2000–2016

Output grew200% over the shown period — from 1 works in 2000 to 3 in 2016.

200020102012201420152016

What are the most-cited papers on Celldex Therapeutics (United States)?

ScholarIQmost cited works

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Edward B. Garon, Naiyer A. Rizvi, Rina Hui, Natasha B. Leighl, Ani Sarkis Balmanoukian, Joseph P. Eder, Amita Patnaik, Charu Aggarwal, Matthew A. Gubens, Leora Horn, Enric Carcereny, Myung‐Ju Ahn, Enriqueta Felip, Jong-Seok Lee, Matthew D. Hellmann, Omid Hamid, Jonathan W. Goldman, Jean‐Charles Soria, Marisa Dolled‐Filhart, Ruth Z. Rutledge, Jin Zhang, Jared Lunceford, Reshma Rangwala, Gregory M. Lubiniecki, Charlotte Roach, Kenneth Emancipator, Leena Gandhi

New England Journal of Medicine. 20156,267 CitationsOPEN ACCESS

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

Eunice L. Kwak, Yung‐Jue Bang, D. Ross Camidge, Alice T. Shaw, Benjamin Solomon, Robert G. Maki, Sai‐Hong Ignatius Ou, Bruce J. Dezube, Pasi A. Jänne, Daniel B. Costa, Marileila Varella‐Garcia, Woo Ho Kim, Thomas J. Lynch, Panos Fidias, Hannah Stubbs, Jeffrey A. Engelman, Lecia V. Sequist, Weiwei Tan, Leena Gandhi, Mari Mino–Kenudson, Greg C. G. Wei, S. Martin Shreeve, Mark J. Ratain, Jeffrey Settleman, James G. Christensen, Daniel A. Haber, Keith D. Wilner, Ravi Salgia, Geoffrey I. Shapiro, Jeffrey W. Clark, A. John Iafrate

New England Journal of Medicine. 20104,513 Citations

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

Shohei Koyama, Esra A. Akbay, Yvonne Y. Li, Grit S. Herter-Sprie, Kevin A. Buczkowski, William G. Richards, Leena Gandhi, Amanda J. Redig, Scott J. Rodig, Hajime Asahina, Robert E. Jones, Meghana Kulkarni, Mari Kuraguchi, Sangeetha Palakurthi, Peter E. Fecci, Bruce E. Johnson, Pasi A. Jänne, Jeffrey A. Engelman, Sidharta P. Gangadharan, Daniel B. Costa, Gordon J. Freeman, Raphael Bueno, F. Stephen Hodi, Glenn Dranoff, Kwok‐Kin Wong, Peter S. Hammerman

Nature Communications. 20161,586 CitationsOPEN ACCESS

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

D. Ross Camidge, Yung‐Jue Bang, Eunice L. Kwak, A. John Iafrate, Marileila Varella‐Garcia, Stephen B. Fox, Gregory J. Riely, Benjamin Solomon, Sai‐Hong Ignatius Ou, Dong‐Wan Kim, Ravi Salgia, P. Fidias, Jeffrey A. Engelman, Leena Gandhi, Pasi A. Jänne, Daniel B. Costa, Geoffrey I. Shapiro, Patricia LoRusso, Katherine Ruffner, Patricia Stephenson, Yiyun Tang, Keith D. Wilner, Jeffrey W. Clark, Alice T. Shaw

The Lancet Oncology. 20121,283 Citations

Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

Scott Gettinger, Leora Horn, Leena Gandhi, David R. Spigel, Scott Antonia, Naiyer A. Rizvi, John D. Powderly, Rebecca S. Heist, Richard D. Carvajal, David M. Jackman, Lecia V. Sequist, David C. Smith, Philip D. Leming, David P. Carbone, Mary Pinder-Schenck, Suzanne L. Topalian, F. Stephen Hodi, Jeffrey A. Sosman, Mario Sznol, David F. McDermott, Drew M. Pardoll, Vindira Sankar, Christoph M. Ahlers, Mark Salvati, Jon M. Wigginton, Matthew D. Hellmann, Georgia Kollia, Ashok Gupta, Julie R. Brahmer

Journal of Clinical Oncology. 20151,197 CitationsOPEN ACCESS